Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that the United States Patent and Trademark Office issued an official Notice of Allowance on one of the Company's patent applications regarding the RAMP® technology. The patent entitled "Comparative Multiple Analyte Immunoassay" is expected to issue in the first quarter of 2011.
"We are pleased to see this patent issued in the U.S.," said Dr. Paul Harris, Chief Scientific Officer. "The patent will allow the Company to use the RAMP® method to measure the relative amounts of two or more analytes with much more accuracy, than if the analytes were first measured and then the amounts compared. This increased accuracy is the result of not having to have standard curves. Instead the amounts are compared directly to each other."
"As we focus on building our cardiac business in the U.S. and abroad, these patents further strengthen the compelling offering to our growing customer base," said S. Wayne Kay, Chief Executive Officer. "This patent also further builds on our solid and growing patent protection surrounding our innovative RAMP® technology program."
New machine learning model achieves breakthrough in heart disease prediction with over 95% accuracy